Inhaled therapeutics for prevention and treatment of pneumonia

Clicks: 117
ID: 269387
2009
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The lungs are the most common site of serious infection owing to their large surface area exposed to the external environment and minimum barrier defense. However, this architecture makes the lungs readily available for topical therapy. Therapeutic aerosols ...
Reference Key
dickey2009expertinhaled Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Amar Safdar, Samuel A. Shelburne, Scott E. Evans, Burton F. Dickey;Amar Safdar;Samuel A. Shelburne;Scott E. Evans;Burton F. Dickey;
Journal expert opinion on drug safety
Year 2009
DOI
10.1517/14740330903036083
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527977/
Keywords
Administration immunity National Center for Biotechnology Information NCBI NLM MEDLINE review animals humans pubmed abstract nih national institutes of health national library of medicine models research support N.I.H. Extramural inhalation anti-infective agents / therapeutic use anti-infective agents / administration & dosage* biological lung / immunology saline solution hypertonic / therapeutic use lung / drug effects amar safdar pneumonia / drug therapy* innate / drug effects cytokines / therapeutic use pmid:19538104 pmc4527977 doi:10.1517/14740330903036083 samuel a shelburne burton f dickey cytokines / administration & dosage* drug delivery systems / instrumentation drug delivery systems / methods* nebulizers and vaporizers / trends pneumonia / prevention & control* hypertonic / administration & dosage*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.